A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

ClinicalTrials.gov ID: NCT01083615

Public ClinicalTrials.gov record NCT01083615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.

Study identification

NCT ID: NCT01083615
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Achieve Life Sciences; Industry
Enrollment: 14 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2010
Primary completion: Feb 28, 2013
Completion: Feb 28, 2013
Last update posted: Oct 11, 2016

2010 – 2013

United States locations

U.S. sites: 20
U.S. states: 19
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	La Verne	California	91705	—
Not listed	Fort Lauderdale	Florida	33308	—
Not listed	Tampa	Florida	33612	—
Not listed	Honolulu	Hawaii	96813	—
Not listed	Urbana	Illinois	61801	—
Not listed	Metairie	Louisiana	70006	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Burlington	Massachusetts	01805	—
Not listed	Detroit	Michigan	48201	—
Not listed	Kansas City	Missouri	64132	—
Not listed	Omaha	Nebraska	68130	—
Not listed	Las Vegas	Nevada	89169	—
Not listed	Syracuse	New York	13210	—
Not listed	Raleigh	North Carolina	27607	—
Not listed	Canton	Ohio	44718	—
Not listed	Oklahoma City	Oklahoma	73120	—
Not listed	Portland	Oregon	97239	—
Not listed	Columbia	South Carolina	29209	—
Not listed	Memphis	Tennessee	38120	—
Not listed	Tyler	Texas	75701	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01083615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 11, 2016 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01083615 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →